Organisations
41 organisations · Activity counts checked 25 October 2026
41 organisations match
Roche / Genentech
CompanySwitzerland84 trials · 12 recruiting · 154 publications in 2021 to 2025
Makes ocrelizumab (Ocrevus), the first therapy approved for PPMS.
Novartis
CompanySwitzerland180 trials · 16 recruiting · 141 publications in 2021 to 2025
Makes fingolimod, siponimod and ofatumumab.
Sanofi
CompanyFrance82 trials · 4 recruiting · 46 publications in 2021 to 2025
Makes teriflunomide and alemtuzumab. Developing tolebrutinib.
Biogen
CompanyUnited States239 trials · 3 recruiting · 142 publications in 2021 to 2025
Makes interferon beta-1a, natalizumab, dimethyl fumarate and diroximel fumarate.
Merck KGaA (EMD Serono)
CompanyGermany111 trials · 0 recruiting · 94 publications in 2021 to 2025
Makes interferon beta-1a (Rebif) and cladribine (Mavenclad).
Bristol Myers Squibb
CompanyUnited States30 trials · 5 recruiting · 31 publications in 2021 to 2025
Makes ozanimod. Developing CAR-T therapy for MS.
Teva Pharmaceuticals
CompanyIsrael51 trials · 0 recruiting · 12 publications in 2021 to 2025
Makes glatiramer acetate (Copaxone).
TG Therapeutics
CompanyUnited States16 trials · 9 recruiting · 3 publications in 2021 to 2025
Makes ublituximab (Briumvi).
Janssen (Johnson & Johnson)
CompanyBelgium10 trials · 0 recruiting · 27 publications in 2021 to 2025
Makes ponesimod (Ponvory).
Immunic Therapeutics
CompanyGermany4 trials · 0 recruiting · 3 publications in 2021 to 2025
Developing vidofludimus calcium.
University of California, San Francisco
Research centreUnited States35 trials · 6 recruiting · 165 publications in 2021 to 2025
MS and neuroinflammation centre in San Francisco.
Johns Hopkins University
Research centreUnited States34 trials · 4 recruiting · 296 publications in 2021 to 2025
MS centre at Johns Hopkins Medicine, Baltimore.
Mayo Clinic
Research centreUnited States15 trials · 2 recruiting · 157 publications in 2021 to 2025
MS clinic and research at Mayo Clinic, Rochester.
Cleveland Clinic
Research centreUnited States24 trials · 1 recruiting · 347 publications in 2021 to 2025
Mellen Center for MS, Cleveland.
Brigham and Women's Hospital
Research centreUnited States19 trials · 5 recruiting · 200 publications in 2021 to 2025
MS centre in Boston, home of the CLIMB study.
University College London
Research centreUnited Kingdom15 trials · 1 recruiting · 347 publications in 2021 to 2025
Queen Square MS Centre, London.
University of Cambridge
Research centreUnited Kingdom3 trials · 0 recruiting · 67 publications in 2021 to 2025
Research on remyelination and myelin repair.
University of Edinburgh
Research centreUnited Kingdom9 trials · 3 recruiting · 66 publications in 2021 to 2025
Anne Rowling Regenerative Neurology Clinic.
Karolinska Institutet
Research centreSweden16 trials · 1 recruiting · 328 publications in 2021 to 2025
MS research and the Swedish MS registry, Stockholm.
Vall d'Hebron (Cemcat)
Research centreSpain3 trials · 1 recruiting · 299 publications in 2021 to 2025
Multiple Sclerosis Centre of Catalonia (Cemcat), Barcelona.
University Hospital Basel
Research centreSwitzerland23 trials · 7 recruiting · 220 publications in 2021 to 2025
MS centre and neurofilament research, Basel.
Charité – Universitätsmedizin Berlin
Research centreGermany31 trials · 4 recruiting · 216 publications in 2021 to 2025
Neuroimmunology and MS research, Berlin.
Amsterdam UMC
Research centreNetherlands16 trials · 3 recruiting · 276 publications in 2021 to 2025
MS Center Amsterdam.
Monash University
Research centreAustralia2 trials · 1 recruiting · 205 publications in 2021 to 2025
MS and neuroimmunology research, Melbourne.
McGill University (Montreal Neurological Institute)
Research centreCanada7 trials · 0 recruiting · 165 publications in 2021 to 2025
The Neuro (Montreal Neurological Institute-Hospital).